Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Ovarian Cancer Survival and Chemotherapy Dosing, Body Mass Index, and Body Surface Area

Ovarian Cancer Survival and Chemotherapy Dosing, Body Mass Index, and Body Surface Area Opinion EDITORIAL Ovarian Cancer Survival and Chemotherapy Dosing, Body Mass Index, and Body Surface Area Are We There Yet? S. Percy Ivy, MD; Jan H. Beumer, PharmD, PhD Thestudyinthisissue ofJAMAOncology by Bandera et al evalu- thereby overestimating the frequency of dose reduction. This ef- atedtheassociationofbodymassindex(BMI)andchemotherapy fect plays an important role in the interpretation of the results. dosing, and the authors related relative dose intensity (RDI) to The association of low RDI with ovarian cancer–specific overall and ovarian cancer–specific mortality. This retrospective survival was only significant for paclitaxel dosed at less than cohort analysis was based on the 70% RDI, which represented 11% of the population. Carbo- Kaiser Permanente Research on platin RDI was not associated with survival, potentially due Related article page 737 OvarianCancerStudyofEpithelial to the previously indicated confounding effect of using lean Ovarian Cancer chemotherapy vs full mass in the C-G formula. Importantly, this means that subcohort (806 patients). Importantly, it is a relatively unselected there are no data to support the conclusion that dose reduc- real-worldcohort,andoneofthelargeststudiedtodate.Theinves- tion of carboplatin is associated with poor survival and that tigators concluded that lower RDI of paclitaxel and carboplatin body size is a predictor for carboplatin dose reduction. was associated with http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Oncology American Medical Association

Ovarian Cancer Survival and Chemotherapy Dosing, Body Mass Index, and Body Surface Area

Ivy, S. Percy; Beumer, Jan H.
JAMA Oncology , Volume 1 (6) – Sep 1, 2015
Download PDF
2 pages

Loading next page...
 
/lp/american-medical-association/ovarian-cancer-survival-and-chemotherapy-dosing-body-mass-index-and-BZuW0p0OY3
Publisher
American Medical Association
Copyright
Copyright 2015 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
2374-2437
eISSN
2374-2445
DOI
10.1001/jamaoncol.2015.1926
pmid
26181495
Publisher site
See Article on Publisher Site

Abstract

Opinion EDITORIAL Ovarian Cancer Survival and Chemotherapy Dosing, Body Mass Index, and Body Surface Area Are We There Yet? S. Percy Ivy, MD; Jan H. Beumer, PharmD, PhD Thestudyinthisissue ofJAMAOncology by Bandera et al evalu- thereby overestimating the frequency of dose reduction. This ef- atedtheassociationofbodymassindex(BMI)andchemotherapy fect plays an important role in the interpretation of the results. dosing, and the authors related relative dose intensity (RDI) to The association of low RDI with ovarian cancer–specific overall and ovarian cancer–specific mortality. This retrospective survival was only significant for paclitaxel dosed at less than cohort analysis was based on the 70% RDI, which represented 11% of the population. Carbo- Kaiser Permanente Research on platin RDI was not associated with survival, potentially due Related article page 737 OvarianCancerStudyofEpithelial to the previously indicated confounding effect of using lean Ovarian Cancer chemotherapy vs full mass in the C-G formula. Importantly, this means that subcohort (806 patients). Importantly, it is a relatively unselected there are no data to support the conclusion that dose reduc- real-worldcohort,andoneofthelargeststudiedtodate.Theinves- tion of carboplatin is associated with poor survival and that tigators concluded that lower RDI of paclitaxel and carboplatin body size is a predictor for carboplatin dose reduction. was associated with

Journal

JAMA Oncology – American Medical Association

Published: Sep 1, 2015

References

  • Impact of chemotherapy dosing on ovarian cancer survival according to body mass index [published online July 2, 2015].
    Bandera, EV; Lee, VS; Rodriguez-Rodriguez, L; Powell, CB; Kushi, LH
  • Prognostic significance of the relative dose intensity of chemotherapy in primary treatment of epithelial ovarian cancer.
    Fauci, JM; Whitworth, JM; Schneider, KE
  • Predictors of reduced relative dose intensity and its relationship to mortality in women receiving multi-agent chemotherapy for epithelial ovarian cancer.
    Hanna, RK; Poniewierski, MS; Laskey, RA
  • Carboplatin dosing in obese women with ovarian cancer: a Gynecologic Oncology Group study.
    Wright, JD; Tian, C; Mutch, DG
  • Impact of obesity on chemotherapy dosing for women with advanced stage serous ovarian cancer in the Australian Ovarian Cancer Study (AOCS).
    Au-Yeung, G; Webb, PM; DeFazio, A; Fereday, S; Bressel, M; Mileshkin, L
  • Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline.
    Griggs, JJ; Mangu, PB; Anderson, H
  • A formula to estimate the approximate surface area if height and weight be known. 1916.
    Du Bois, D; Du Bois, EF
  • Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001.
    Baker, SD; Verweij, J; Rowinsky, EK
  • Body-surface area-based chemotherapy dosing: appropriate in the 21st century?
    Beumer, JH; Chu, E; Salamone, SJ
  • Without therapeutic drug monitoring, there is no personalized cancer care.
    Beumer, JH
  • Phase I studies with carboplatin at the Royal Marsden Hospital.
    Calvert, AH; Harland, SJ; Newell, DR; Siddik, ZH; Harrap, KR
  • Prediction of creatinine clearance from serum creatinine.
    Cockcroft, DW; Gault, MH
  • Functional range of creatinine clearance for renal drug dosing: a practical solution to the controversy of which weight to use in the Cockcroft-Gault equation.
    Brown, DL; Masselink, AJ; Lalla, CD
  • Does body mass index affect progression-free or overall survival in patients with ovarian cancer? results from SCOTROC I trial.
    Barrett, SV; Paul, J; Hay, A; Vasey, PA; Kaye, SB; Glasspool, RM
  • Extremely high exposures in an obese patient receiving high-dose cyclophosphamide, thiotepa and carboplatin.
    De Jonge, ME; Mathôt, RA; Van Dam, SM; Beijnen, JH; Rodenhuis, S